| Characteristics . | 12-Week Group, n = 322 . | 20-Week Group, n = 336 . |
|---|---|---|
| Study site | ||
| Sunpasitthiprasong Hospital, Ubon Ratchathani | 161 (50) | 164 (49) |
| Srinagarind Hospital, Khon Kaen | 42 (13) | 43 (13) |
| Khon Kaen Hospital, Khon Kaen | 15 (5) | 18 (5) |
| Nakhonphanom Hospital, Nakhonphanom | 47 (15) | 52 (15) |
| Udon Thani Hospital, Udon Thani | 29 (9) | 30 (9) |
| Srisaket Hospital, Srisaket | 13 (4) | 13 (4) |
| Chaiyaphum Hospital, Chaiyaphum | 12 (4) | 13 (4) |
| Maharat Nakhonratchasima Hospital, Nakhonratchasima | 3 (1) | 3 (1) |
| Sex, men | 212 (66) | 228 (68) |
| Age, years | 54 (45–63) | 54 (44–62) |
| Underlying diseases | ||
| Diabetes mellitus | 231 (72) | 233 (69) |
| Chronic kidney disease or renal stones | 52 (16) | 37 (11) |
| Chronic liver disease | 13 (4) | 21 (6) |
| Thalassemia | 5 (2) | 12 (4) |
| Other diseasesa | 33 (10) | 30 (9) |
| Distribution of melioidosisb | ||
| Localized | 122 (38) | 110 (33) |
| Multifocal | 22 (7) | 17 (5) |
| Bacteremic | 130 (40) | 154 (46) |
| Disseminated | 48 (15) | 55 (16) |
| Organ involvementc | ||
| Pneumonia | 118 (37) | 115 (34) |
| Skin or subcutaneous abscess | 74 (23) | 66 (20) |
| Splenic abscess | 42 (13) | 44 (13) |
| Liver abscess | 30 (9) | 44 (13) |
| Arthritis | 33 (10) | 27 (8) |
| Urinary tract infection | 17 (5) | 30 (9) |
| Lymphadenopathy | 11 (3) | 5 (1) |
| Otherd | 13 (4) | 16 (5) |
| Duration of parenteral antimicrobials before the start of oral eradication treatment | ||
| None | 18 (6) | 12 (4) |
| 1–14 days | 119 (37) | 143 (43) |
| 15–28 days | 156 (48) | 148 (44) |
| >29 days | 29 (9) | 33 (10) |
| Regimen of oral eradication treatment during the first 12 weeks of oral eradication treatment | ||
| TMP-SMX | 302 (94) | 313 (93) |
| TMP-SMX plus doxycycline | 20 (6) | 23 (7) |
| Dosage of TMP-SMX received | ||
| 160/800 mg twice daily | 7 (2) | 11 (3) |
| 240/1200 mg twice daily | 202 (63) | 192 (57) |
| 320/1600 mg twice daily | 113 (35) | 133 (40) |
| Characteristics . | 12-Week Group, n = 322 . | 20-Week Group, n = 336 . |
|---|---|---|
| Study site | ||
| Sunpasitthiprasong Hospital, Ubon Ratchathani | 161 (50) | 164 (49) |
| Srinagarind Hospital, Khon Kaen | 42 (13) | 43 (13) |
| Khon Kaen Hospital, Khon Kaen | 15 (5) | 18 (5) |
| Nakhonphanom Hospital, Nakhonphanom | 47 (15) | 52 (15) |
| Udon Thani Hospital, Udon Thani | 29 (9) | 30 (9) |
| Srisaket Hospital, Srisaket | 13 (4) | 13 (4) |
| Chaiyaphum Hospital, Chaiyaphum | 12 (4) | 13 (4) |
| Maharat Nakhonratchasima Hospital, Nakhonratchasima | 3 (1) | 3 (1) |
| Sex, men | 212 (66) | 228 (68) |
| Age, years | 54 (45–63) | 54 (44–62) |
| Underlying diseases | ||
| Diabetes mellitus | 231 (72) | 233 (69) |
| Chronic kidney disease or renal stones | 52 (16) | 37 (11) |
| Chronic liver disease | 13 (4) | 21 (6) |
| Thalassemia | 5 (2) | 12 (4) |
| Other diseasesa | 33 (10) | 30 (9) |
| Distribution of melioidosisb | ||
| Localized | 122 (38) | 110 (33) |
| Multifocal | 22 (7) | 17 (5) |
| Bacteremic | 130 (40) | 154 (46) |
| Disseminated | 48 (15) | 55 (16) |
| Organ involvementc | ||
| Pneumonia | 118 (37) | 115 (34) |
| Skin or subcutaneous abscess | 74 (23) | 66 (20) |
| Splenic abscess | 42 (13) | 44 (13) |
| Liver abscess | 30 (9) | 44 (13) |
| Arthritis | 33 (10) | 27 (8) |
| Urinary tract infection | 17 (5) | 30 (9) |
| Lymphadenopathy | 11 (3) | 5 (1) |
| Otherd | 13 (4) | 16 (5) |
| Duration of parenteral antimicrobials before the start of oral eradication treatment | ||
| None | 18 (6) | 12 (4) |
| 1–14 days | 119 (37) | 143 (43) |
| 15–28 days | 156 (48) | 148 (44) |
| >29 days | 29 (9) | 33 (10) |
| Regimen of oral eradication treatment during the first 12 weeks of oral eradication treatment | ||
| TMP-SMX | 302 (94) | 313 (93) |
| TMP-SMX plus doxycycline | 20 (6) | 23 (7) |
| Dosage of TMP-SMX received | ||
| 160/800 mg twice daily | 7 (2) | 11 (3) |
| 240/1200 mg twice daily | 202 (63) | 192 (57) |
| 320/1600 mg twice daily | 113 (35) | 133 (40) |
Data are shown as n (%) or median (interquartile range).
Abbreviations: HIV, human immunodeficiency virus; TMP-SMX, trimethoprim-sulfamethoxazole.
aIncluded steroid intake (19), chronic obstructive pulmonary disease (13), cancer (10), gouty arthritis (10), ischemic heart disease (9), connective tissue diseases (8) and immunosuppressive drug intake (4), and HIV infection (3)
bLocalized was defined as a single focus of infection and a negative blood culture result; multifocal as >1 noncontiguous focus of infection and a negative blood culture result; bacteremic as a positive blood culture result plus a single or no identifiable focus of infection; and disseminated as a positive blood culture result plus >1 noncontiguous focus of infection
cOrgan involvement was defined as the presence of clinical features and/or clinical specimen taken from the organ that was culture positive for Burkholderia pseudomallei
dIncluded pleuritis or pleural effusion (11), mycotic aneurysm (6), prostatic abscess (3), sinusitis (3), central nervous system infection (2), peritonitis (2), pericarditis (1), and testicular abscess (1)
| Characteristics . | 12-Week Group, n = 322 . | 20-Week Group, n = 336 . |
|---|---|---|
| Study site | ||
| Sunpasitthiprasong Hospital, Ubon Ratchathani | 161 (50) | 164 (49) |
| Srinagarind Hospital, Khon Kaen | 42 (13) | 43 (13) |
| Khon Kaen Hospital, Khon Kaen | 15 (5) | 18 (5) |
| Nakhonphanom Hospital, Nakhonphanom | 47 (15) | 52 (15) |
| Udon Thani Hospital, Udon Thani | 29 (9) | 30 (9) |
| Srisaket Hospital, Srisaket | 13 (4) | 13 (4) |
| Chaiyaphum Hospital, Chaiyaphum | 12 (4) | 13 (4) |
| Maharat Nakhonratchasima Hospital, Nakhonratchasima | 3 (1) | 3 (1) |
| Sex, men | 212 (66) | 228 (68) |
| Age, years | 54 (45–63) | 54 (44–62) |
| Underlying diseases | ||
| Diabetes mellitus | 231 (72) | 233 (69) |
| Chronic kidney disease or renal stones | 52 (16) | 37 (11) |
| Chronic liver disease | 13 (4) | 21 (6) |
| Thalassemia | 5 (2) | 12 (4) |
| Other diseasesa | 33 (10) | 30 (9) |
| Distribution of melioidosisb | ||
| Localized | 122 (38) | 110 (33) |
| Multifocal | 22 (7) | 17 (5) |
| Bacteremic | 130 (40) | 154 (46) |
| Disseminated | 48 (15) | 55 (16) |
| Organ involvementc | ||
| Pneumonia | 118 (37) | 115 (34) |
| Skin or subcutaneous abscess | 74 (23) | 66 (20) |
| Splenic abscess | 42 (13) | 44 (13) |
| Liver abscess | 30 (9) | 44 (13) |
| Arthritis | 33 (10) | 27 (8) |
| Urinary tract infection | 17 (5) | 30 (9) |
| Lymphadenopathy | 11 (3) | 5 (1) |
| Otherd | 13 (4) | 16 (5) |
| Duration of parenteral antimicrobials before the start of oral eradication treatment | ||
| None | 18 (6) | 12 (4) |
| 1–14 days | 119 (37) | 143 (43) |
| 15–28 days | 156 (48) | 148 (44) |
| >29 days | 29 (9) | 33 (10) |
| Regimen of oral eradication treatment during the first 12 weeks of oral eradication treatment | ||
| TMP-SMX | 302 (94) | 313 (93) |
| TMP-SMX plus doxycycline | 20 (6) | 23 (7) |
| Dosage of TMP-SMX received | ||
| 160/800 mg twice daily | 7 (2) | 11 (3) |
| 240/1200 mg twice daily | 202 (63) | 192 (57) |
| 320/1600 mg twice daily | 113 (35) | 133 (40) |
| Characteristics . | 12-Week Group, n = 322 . | 20-Week Group, n = 336 . |
|---|---|---|
| Study site | ||
| Sunpasitthiprasong Hospital, Ubon Ratchathani | 161 (50) | 164 (49) |
| Srinagarind Hospital, Khon Kaen | 42 (13) | 43 (13) |
| Khon Kaen Hospital, Khon Kaen | 15 (5) | 18 (5) |
| Nakhonphanom Hospital, Nakhonphanom | 47 (15) | 52 (15) |
| Udon Thani Hospital, Udon Thani | 29 (9) | 30 (9) |
| Srisaket Hospital, Srisaket | 13 (4) | 13 (4) |
| Chaiyaphum Hospital, Chaiyaphum | 12 (4) | 13 (4) |
| Maharat Nakhonratchasima Hospital, Nakhonratchasima | 3 (1) | 3 (1) |
| Sex, men | 212 (66) | 228 (68) |
| Age, years | 54 (45–63) | 54 (44–62) |
| Underlying diseases | ||
| Diabetes mellitus | 231 (72) | 233 (69) |
| Chronic kidney disease or renal stones | 52 (16) | 37 (11) |
| Chronic liver disease | 13 (4) | 21 (6) |
| Thalassemia | 5 (2) | 12 (4) |
| Other diseasesa | 33 (10) | 30 (9) |
| Distribution of melioidosisb | ||
| Localized | 122 (38) | 110 (33) |
| Multifocal | 22 (7) | 17 (5) |
| Bacteremic | 130 (40) | 154 (46) |
| Disseminated | 48 (15) | 55 (16) |
| Organ involvementc | ||
| Pneumonia | 118 (37) | 115 (34) |
| Skin or subcutaneous abscess | 74 (23) | 66 (20) |
| Splenic abscess | 42 (13) | 44 (13) |
| Liver abscess | 30 (9) | 44 (13) |
| Arthritis | 33 (10) | 27 (8) |
| Urinary tract infection | 17 (5) | 30 (9) |
| Lymphadenopathy | 11 (3) | 5 (1) |
| Otherd | 13 (4) | 16 (5) |
| Duration of parenteral antimicrobials before the start of oral eradication treatment | ||
| None | 18 (6) | 12 (4) |
| 1–14 days | 119 (37) | 143 (43) |
| 15–28 days | 156 (48) | 148 (44) |
| >29 days | 29 (9) | 33 (10) |
| Regimen of oral eradication treatment during the first 12 weeks of oral eradication treatment | ||
| TMP-SMX | 302 (94) | 313 (93) |
| TMP-SMX plus doxycycline | 20 (6) | 23 (7) |
| Dosage of TMP-SMX received | ||
| 160/800 mg twice daily | 7 (2) | 11 (3) |
| 240/1200 mg twice daily | 202 (63) | 192 (57) |
| 320/1600 mg twice daily | 113 (35) | 133 (40) |
Data are shown as n (%) or median (interquartile range).
Abbreviations: HIV, human immunodeficiency virus; TMP-SMX, trimethoprim-sulfamethoxazole.
aIncluded steroid intake (19), chronic obstructive pulmonary disease (13), cancer (10), gouty arthritis (10), ischemic heart disease (9), connective tissue diseases (8) and immunosuppressive drug intake (4), and HIV infection (3)
bLocalized was defined as a single focus of infection and a negative blood culture result; multifocal as >1 noncontiguous focus of infection and a negative blood culture result; bacteremic as a positive blood culture result plus a single or no identifiable focus of infection; and disseminated as a positive blood culture result plus >1 noncontiguous focus of infection
cOrgan involvement was defined as the presence of clinical features and/or clinical specimen taken from the organ that was culture positive for Burkholderia pseudomallei
dIncluded pleuritis or pleural effusion (11), mycotic aneurysm (6), prostatic abscess (3), sinusitis (3), central nervous system infection (2), peritonitis (2), pericarditis (1), and testicular abscess (1)
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
